The article "Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation" describes the case study of a patient with advanced non-small cell lung cancer (NSCLC) that had progressed after initial chemotherapy treatment. The patient underwent genomic profiling of their tumor tissue, and the results were analyzed using the computational decision support tool Genomate. The analysis identified a genomic alteration in the tumor that was potentially targetable by an available drug, and the patient was treated with the targeted therapy afatinib. The patient showed a partial response to the treatment, with a reduction in tumor size and improvement in symptoms.
- Genomic profiling of the patient's tumor tissue identified a genomic alteration that was potentially targetable by an available drug.
- Computational decision support tool Genomate was used to analyze the genomic data and identify personalized treatment options for the patient.
- The patient was treated with the targeted therapy afatinib and showed a partial response to the treatment.
- This case study highlights the potential of precision medicine approaches like genomic profiling and computational decision support tools to identify personalized treatment options for NSCLC patients.
- The use of targeted therapies based on genomic alterations may improve treatment outcomes for NSCLC patients who have progressed after initial chemotherapy.
Read the entire article here.
Urbán L, Dóczi R, Vodicska B, Tihanyi D, Horváth M, Kormos D, Takács I, Pápai-Székely Z, Póka-Farkas Z, Várkondi E, Schwáb R, Hegedüs C, Vályi-Nagy I, Peták I.
Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18. PMID: 33082101.